Growth-promoting agents such as growth hormone therapy with or without GnRH analog have been recommended to improve the final adult height only in CAH patients with markedly short predicted adult height, although prospective randomized controlled studies are still needed to determine their efficacy to preserve the final height (17). Here, GNRH1 is linked to congenital adrenal hyperplasia.